American Heart Journal
Volume 159, Issue 3 , Pages 361-369.e4 , March 2010

Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events

  • Tamio Teramoto, MD, PhD

      Affiliations

    • Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
    • Corresponding Author InformationReprint requests: Tamio Teramoto, MD, PhD, Internal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8606, Japan.
    • ,
  • Kazuyuki Shimada, MD, PhD

      Affiliations

    • Department of Cardiology, Jichi Medical University Hospital, Tochigi, Japan
    • ,
  • Shinichiro Uchiyama, MD, PhD

      Affiliations

    • Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan
    • ,
  • Masahiro Sugawara, MD

      Affiliations

    • Japan Physicians Association, Japan
    • ,
  • Yoshio Goto, MD, PhD

      Affiliations

    • Japan Physicians Association, Japan
    • ,
  • Nobuhiro Yamada, MD, PhD

      Affiliations

    • Tsukuba University Hospital, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    • ,
  • Shinichi Oikawa, MD, PhD

      Affiliations

    • Department of Medicine, Nippon Medical University, Tokyo, Japan
    • ,
  • Katsuyuki Ando, MD, PhD

      Affiliations

    • Division of Molecular Cardiovascular Metabolism, Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
    • ,
  • Naoki Ishizuka, PhD

      Affiliations

    • Division of Preventive Medicine, Department of Community Health and Medicine, Research Institute, International Medical Center of Japan, Tokyo, Japan
    • ,
  • Tsutomu Yamazaki, MD, PhD

      Affiliations

    • Faculty of Medicine, Department of Clinical Epidemiology and Systems, Graduate School of Medicine, Center for Epidemiology and Preventive Medicine, The University of Tokyo, Tokyo, Japan
    • ,
  • Kenji Yokoyama, MD, PhD

      Affiliations

    • Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    • ,
  • Mitsuru Murata, MD, PhD

      Affiliations

    • Clinical Laboratory, Keio University School of Medicine, Tokyo, Japan
    • ,
  • Yasuo Ikeda, MD, PhD

      Affiliations

    • Major in Life Science and Medical Bioscience Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan

Received 22 May 2009 ,Accepted 25 November 2009.

References 

  1. The Ministry of Health, Labour and Welfare, Japan . Ministry of Health, Labour and Welfare Report: 2007. [Japanese]. Available at: http://www.mhlw.go.jp/wp/hakusyo/kousei/07/dl/0102-a.pdfPublished 2007. Last accessed July 30, 2009
  2. Antithrombotic Trialists'Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  3. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890–911
  4. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for health care professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577–1579
  5. Albers GW, Hart RG, Lutsep HL, et al. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke. 1999;30:2502–2511
  6. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434–1503
  7. Royal College of Physicians . National clinical guidelines for stroke. 2nd ed.. London: RCP; 2004;Prepared by the Intercollegiate Stroke Working Party
  8. The Joint Study Group 1998-1999. Guidelines for secondary prevention of myocardial infarction. Jpn Circ J. 2000;64(Suppl IV):1081–1127[Japanese]
  9. The Joint Study Group 2000-2001. Guidelines for management of acute coronary syndrome without persistent ST-segment elevation (JCS 2002). Circ J. 2002;66(Suppl VI):1123–1163[Japanese]
  10. Joint Committee on Guidelines for the Management of Stroke . Japanese guidelines for the management of stroke (2004). Tokyo: Kyowa Kikaku, Inc.; 2004;[Japanese]
  11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129–135
  12. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313–316
  13. The Medical Research Council's General Practice Research Framework . Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233–241
  14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  15. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89–95
  16. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304
  17. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860
  18. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141
  19. Yamazaki T, Goto S, Shigematsu H, et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan: results from domestic baseline data of the REduction of Atherothrombosis for Continued Health (REACH) Registry. Circ J. 2007;71:995–1003
  20. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  21. World Health Organization . Mortality Database, 2007. Available at: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xlsLast accessed July 30, 2009
  22. Hansson L, Hedner T, Dahlof B. Prospective randomized blinded end-point (PROBE) Study: a novel design for intervention trials. Blood Press. 1992;1:113–119
  23. Committee on Guidelines for the Management of Hypertension in the Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004). The Japanese Society of Hypertension; 2004;[Japanese]
  24. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases 2002. Japan Atherosclerosis Society; 2002;[Japanese]
  25. Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan. Tokyo: Nankodo Co Ltd; 2004;[Japanese]
  26. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a Statement From the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543–2549
  27. Arai H, Yamamoto A, Matsuzawa Y, et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb. 2006;13:202–208
  28. Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. Guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004;117:459–468
  29. Ohkubo T, Obara T, Funahashi J, et al. and the J-HOME Study Group Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res. 2004;27:755–763
  30. Teramoto T, Kashiwagi A, Mabuchi H for the J-LAP Investigators. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults; a study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res Clin Exp. 2005;66:80–95
  31. Sone H, Kawai K, Takagi H, et al. Outcome of one-year of specialist care of patients with type 2 diabetes: a multi-center prospective survey (JDDM 2). Intern Med. 2006;45:589–597
  32. Yamamoto T, Sanaka M, Nagasawa K, et al. Gastroduodenal mucosal injury in patients on antiplatelet therapy. Thromb Res. 2007;120:465–469[Epub 2007 Jan 24]
  33. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long-term use of aspirin: meta-analysis. BMJ. 2000;321:1183–1187

 RCT#:NCT00225849.

PII: S0002-8703(09)00955-7

doi: 10.1016/j.ahj.2009.11.030

American Heart Journal
Volume 159, Issue 3 , Pages 361-369.e4 , March 2010

Article Tools

* Image Usage & Resolution